Clinical Trial: Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC

U.S., July 30 -- ClinicalTrials.gov registry received information related to the study (NCT07733830) titled 'Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC' on July 20.

Brief Summary: A total of 120 patients with unresectable, locally advanced esophageal squamous cell carcinoma patients will be enrolled in this study and randomly divided into two groups.

Arm A: After 2 cycles of induction adebrelimab plus chemotherapy, patients will be treated with concurrent chemoradiotherapy (50.4Gy/1.8Gy/28f), and adebrelimab will maintain to PD or for a maximum of 15 cycles.

Arm B: Patients will be treated with concurrent chemoradiotherapy (50.4Gy/1.8Gy/28f) and adebrelimab will maintain to PD or for a maxim...